Speaking on the news, Dr Ross O’Neill, Founding CEO of Neuromod said, “We’re delighted to announce the publication of positive results from the TENT-A2 clinical trial which show greater improvement in tinnitus symptoms from treatment with Lenire. Tinnitus remains one of the largest unmet clinical needs globally and I’m proud that Neuromod is at the forefront of developing bimodal neuromodulation technology to treat chronic tinnitus.